연구성과로 돌아가기
2022 연구성과 (68 / 280)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| WoS | SCOPUS | Document Type | Document Title | Abstract | Authors | Affiliation | ResearcherID (WoS) | AuthorsID (SCOPUS) | Author Email(s) | Journal Name | JCR Abbreviation | ISSN | eISSN | Volume | Issue | WoS Edition | WoS Category | JCR Year | IF | JCR (%) | FWCI | FWCI Update Date | WoS Citation | SCOPUS Citation | Keywords (WoS) | KeywordsPlus (WoS) | Keywords (SCOPUS) | KeywordsPlus (SCOPUS) | Language | Publication Stage | Publication Year | Publication Date | DOI | JCR Link | DOI Link | WOS Link | SCOPUS Link |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ○ | ○ | Article | Visible-light NO photolysis of ruthenium nitrosyl complexes with N2O2 ligands bearing π-extended rings and their photorelease dynamics | NO photorelease and its dynamics for two {RuNO}(6) complexes, Ru(salophen)(NO)Cl (1) and Ru(naphophen)(NO)Cl (2), with salen-type ligands bearing pi-extended systems (salophenH(2) = N,N'-(1,2-phenylene)-bis(salicylideneimine) and naphophenH(2) = N,N'-1,2- phenylene-bis(2-hydroxy-1- naphthylmethyl-eneimine)) were investigated. NO photolysis was performed under white room light and monitored by UV/Vis, EPR, and NMR spectroscopies. NO photolysis was also performed under 459 and 489 nm irradiation for 1 and 2, respectively. The photochemical quantum yields of the NO photolysis (phi(NO)) of both 1 and 2 were determined to be 9% at the irradiation wavelengths. The structural and spectroscopic characteristics of the complexes before and after the photolysis confirmed the conversion of diamagnetic Ru(II)(L)(Cl)-NO+ to paramagnetic S = 1/2 Ru(III)(L)(Cl)-solvent by photons (L = salophen(2-) and naphophen(2)(-)). The photoreleased NO radicals were detected by spin-trapping EPR. DFT and TDDFT calculations found that the photoactive bands are configured as mostly the ligand-to-ligand charge transfer (LLCT) of pi(L) -> pi*(Ru-NO), suggesting that the NO photorelease was initiated by the LLCT. Dynamics of NO photorelease from the complexes in DMSO under 320 nm excitation were investigated by femtosecond (fs) time-resolved mid-IR spectroscopy. The primary photorelease of NO occurred for less than 0.32 ps after the excitation. The rate constants (k(-1)) of the geminate rebinding of NO to the photolyzed 1 and 2 were determined to be (15 ps)(-1) and (13 ps)(-1), respectively. The photochemical quantum yields of NO photolysis (phi(NO), lambda = 320 nm) were estimated to be no higher than 14% for 1 and 11% for 2, based on the analysis of the fs time-resolved IR data. The results of fs time-resolved IR spectroscopy and theoretical calculations provided some insight into the overall kinetic reaction pathway, localized electron pathway or resonance pathway, of the NO photolysis of 1 and 2. Overall, our study found that the investigated {RuNO}(6) complexes, 1 and 2, with planar N2O2 ligands bearing pi-extended rings effectively released NO under visible light. | Kim, Minyoung; Park, Seongchul; Song, Dayoon; Moon, Dohyun; You, Youngmin; Lim, Manho; Lee, Hong-In | Kyungpook Natl Univ, Dept Chem, Daegu 41566, South Korea; Kyungpook Natl Univ, Green Nano Res Ctr, Daegu 41566, South Korea; Pusan Natl Univ, Dept Chem, Busan 46241, South Korea; Pusan Natl Univ, Chem Inst Funct Mat, Busan 46241, South Korea; Ewha Womans Univ, Div Chem Engn & Mat Sci, Seoul 03760, South Korea; Ewha Womans Univ, Grad Program Syst Hlth Sci & Engn, Seoul 03760, South Korea; Pohang Accelerator Lab, Pohang 37673, Gyeongbuk, South Korea | Moon, Dohyun/AAW-9759-2021; Lee, Hong-In/IXN-3185-2023 | 57223366791; 56074397100; 57464126000; 7202057834; 24759463600; 7201473172; 8509535000 | mhlim@pusan.ac.kr;leehi@knu.ac.kr; | DALTON TRANSACTIONS | DALTON T | 1477-9226 | 1477-9234 | 51 | 30 | SCIE | CHEMISTRY, INORGANIC & NUCLEAR | 2022 | 4 | 15.5 | 0.42 | 2025-06-25 | 3 | 4 | NITRIC-OXIDE NO; DENSITY-FUNCTIONAL THEORY; BIOLOGICAL-ACTIVITY; LINKAGE ISOMERISM; SALEN-NITROSYL; BASIS-SETS; AB-INITIO; RELEASE; EPR; REACTIVITY | English | 2022 | 2022-08-02 | 10.1039/d2dt01019d | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||||
| ○ | ○ | Article | A compatibility evaluation between the physiologically based pharmacokinetic (PBPK) model and the compartmental PK model using the lumping method with real cases | Pharmacokinetic (PK) modeling is a useful method for investigating drug absorption, distribution, metabolism, and excretion. The most commonly used mathematical models in PK modeling are the compartment model and physiologically based pharmacokinetic (PBPK) model. Although the theoretical characteristics of each model are well known, there have been few comparative studies of the compatibility of the models. Therefore, we evaluated the compatibility of PBPK and compartment models using the lumping method with 20 model compounds. The PBPK model was theoretically reduced to the lumped model using the principle of grouping tissues and organs that show similar kinetic behaviors. The area under the concentration-time curve (AUC) based on the simulated concentration and PK parameters (drug clearance [CL], central volume of distribution [Vc], peripheral volume of distribution [Vp]) in each model were compared, assuming administration to humans. The AUC and PK parameters in the PBPK model were similar to those in the lumped model within the 2-fold range for 17 of 20 model compounds (85%). In addition, the relationship of the calculated Vd/fu (volume of distribution [Vd], drug-unbound fraction [fu]) and the accuracy of AUC between the lumped model and compartment model confirmed their compatibility. Accordingly, the compatibility between PBPK and compartment models was confirmed by the lumping method. This method can be applied depending on the requirement of compatibility between the two models. | Ryu, Hyo-jeong; Kang, Won-ho; Kim, Taeheon; Kim, Jae Kyoung; Shin, Kwang-Hee; Chae, Jung-woo; Yun, Hwi-yeol | Chungnam Natl Univ, Coll Pharm, Dept Pharm, Daejeon, South Korea; Korea Adv Inst Sci & Technol, Dept Math Sci, Daejeon, South Korea; Inst for Basic Sci Korea, Biomed Math Grp, Daejeon, South Korea; Kyungpook Natl Univ, Res Inst Pharmaceut Sci, Coll Pharm, Daegu, South Korea | Kim, Jae Kyoung/F-1297-2015 | 57221648756; 57219297421; 57202769917; 56150933800; 35216279300; 36240260000; 15133707900 | jwchae@cnu.ac.kr;hyyun@cnu.ac.kr; | FRONTIERS IN PHARMACOLOGY | FRONT PHARMACOL | 1663-9812 | 13 | SCIE | PHARMACOLOGY & PHARMACY | 2022 | 5.6 | 15.6 | 0.67 | 2025-06-25 | 5 | 5 | pharmacokinetic modeling; physiologically based pharmacokinetic (PBPK) model; lumping method; compartment model; compatibility | SIMULATION; STRATEGY; PRINCIPLES; PREDICTION | compartment model; compatibility; lumping method; pharmacokinetic modeling; physiologically based pharmacokinetic (PBPK) model | English | 2022 | 2022-08-12 | 10.3389/fphar.2022.964049 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||||
| ○ | ○ | Article | A pharmacodynamic investigation to assess the synergism of orbifloxacin and propyl gallate against Escherichia coli | Escherichia coli (E. coli) infections are becoming increasingly difficult to treat, as antibiotic-resistant variants proliferate. Studies on novel methods to combat the spread of resistance and improve the performance of current antibiotics are vital. We aimed to boost the efficacy of the antibiotic orbifloxacin (ORB) against E. coli by combining it with a phenolic component, propyl gallate (PG). The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of ORB against the E. coli KVCC 1423 resistant strain were 128 mu g/ml and 256 mu g/ml, respectively. However, the MIC of ORB for the remaining E. coli strains was 0.5 mu g/ml-2 mu g/ml. For the combination of PG and ORB, the lowest fractional inhibitory concentration (FIC) index was less than 0.5, and the combination decreased the MIC of both drugs by 74%. The time-kill assay revealed the killing properties of both the drugs and the pharmacodynamic model (PD model) confirmed the strong killing properties of the combination as compared to the individual activities of the drugs. The ratio between MIC and mutant prevention concentration of ORB against E. coli 1400306 and 1,423 were 1:32 and 1:8, respectively. The combination of ORB and PG showed strong biofilm eradication and inhibited the motility of bacteria. The cell viability of the combination was > 80%. Therefore, we believe that ORB and PG in combination could be a possible antibacterial candidate that could minimize resistance and improve antibiotic potential. | Abbas, Muhammad Aleem; Lee, Eon-Bee; Boby, Naila; Biruhanu, Biruk Tesfaye; Park, Seung-Chun | Kyungpook Natl Univ, Cardiovasc Inst, Coll Vet Med, Lab Vet Pharmacokinet & Pharmacodynam, Daegu, Gyeongsangbugdo, South Korea; Kyungpook Natl Univ, Sch Med, Cardiovasc Res Inst, Daegu, Gyeongsangbugdo, South Korea | Park, Seung-Chun/AAV-3388-2021; Lee, Jung Bok/HHZ-3200-2022; Boby, Naila/GRE-8096-2022; Abbas, Muhammad Aleem/GLT-8362-2022 | 57216531374; 57216526135; 57197787296; 57913007200; 7501832396 | btbtes@gmail.com;parksch@knu.ac.kr; | FRONTIERS IN PHARMACOLOGY | FRONT PHARMACOL | 1663-9812 | 13 | SCIE | PHARMACOLOGY & PHARMACY | 2022 | 5.6 | 15.6 | 0.93 | 2025-06-25 | 7 | 7 | synergistic antimicrobial combinations; antibiotics resistance; Orbifloxacin; propyl gallate; Escherichia coli; Synergism; phenolic compound; pharmacodynamic model | QUINOLONE RESISTANCE; SWARMING MOTILITY; DIFFERENTIATION; SALMONELLA; MECHANISMS | antibiotics resistance; Escherichia coli; Orbifloxacin; pharmacodynamic model; phenolic compound; propyl gallate; Synergism; synergistic antimicrobial combinations | gallic acid propyl ester; orbifloxacin; antibacterial activity; antibiotic resistance; antimicrobial activity; Article; bacterial clearance; bacterial strain; biofilm; cell viability; controlled study; drug efficacy; drug potentiation; Escherichia coli; fractional inhibitory concentration index; minimum bactericidal concentration; minimum inhibitory concentration; nonhuman; pharmacodynamic parameters | English | 2022 | 2022-09-15 | 10.3389/fphar.2022.989395 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Article | Characterization of Kinesin Family Member 2C as a Proto-Oncogene in Cervical Cancer | Kinesin family member 2C (KIF2C) is known as an oncogenic gene to regulate tumor progression and metastasis. However, its pan-cancer analysis has not been reported. In this study, we comprehensively analyzed the characteristics of KIF2C in various cancers. We found that KIF2C was highly expressed and corresponded to a poor prognosis in various cancers. We also found a significant correlation between KIF2C and clinicopathological characteristics, particularly in cervical cancer, which is the most common gynecological malignancy and is the second leading cause of cancer-related deaths among women worldwide. KIF2C mutation is strongly associated with the survival rate of cervical cancer, and KIF2C expression was significantly upregulated in cervical cancer tissues and cervical cancer cells. Moreover, KIF2C promoted cervical cancer cells proliferation, invasion, and migration in vitro and as well increased tumor growth in vivo. KIF2C knockdown promotes the activation of the p53 signaling pathway by regulating the expression of related proteins. The rescue assay with KIF2C and p53 double knockdown partially reversed the inhibitory influence of KIF2C silencing on cervical cancer processes. In summary, our study provided a relatively comprehensive description of KIF2C as an oncogenic gene and suggested KIF2C as a therapeutic target for cervical cancer. | Yang, Jing; Wu, Zimeng; Yang, Li; Jeong, Ji-Hak; Zhu, Yuanhang; Lu, Jie; Wang, Baojin; Wang, Nannan; Wang, Yan; Shen, Ke; Li, Ruiqing | Zhengzhou Univ, Affiliated Hosp 3, Dept Obstet & Gynecol, Zhengzhou, Peoples R China; Henan Int Joint Lab Ovarian Malignancies, Zhengzhou, Peoples R China; Zhengzhou Key Lab Endometrial Dis Prevent & Treat, Zhengzhou, Peoples R China; Kyungpook Natl Univ, Coll Pharm, Res Inst Pharmaceut Sci, Daegu, South Korea | zhang, yi/HKV-8165-2023; Liu, Tongliang/AAA-1506-2021 | 57448683200; 57218527415; 57213065734; 55913671500; 57195683972; 57218531873; 57193131530; 59807150100; 56941958800; 57448733400; 57450072300 | zdsfyyangli@163.com; | FRONTIERS IN PHARMACOLOGY | FRONT PHARMACOL | 1663-9812 | 12 | SCIE | PHARMACOLOGY & PHARMACY | 2022 | 5.6 | 15.6 | 2 | 2025-06-25 | 16 | 15 | KIF2C; cervical cancer; P53 signaling pathway; molecularly targeted therapy; pan-cancer analysis | CELL-CYCLE; EXPRESSION; OVEREXPRESSION; ELIMINATION; GROWTH | cervical cancer; KIF2C; molecularly targeted therapy; P53 signaling pathway; pan-cancer analysis | kinesin; protein p53; adult; animal experiment; animal model; animal tissue; Article; cancer prognosis; cancer staging; cancer survival; carcinogenicity; cell invasion; cell migration; cell proliferation; clinical feature; controlled study; CRISPR-CAS9 system; disease free survival; female; gene expression; gene mutation; gene silencing; gene targeting; genetic analysis; histopathology; human; human cell; human tissue; immunohistochemistry; KIF2C gene; major clinical study; mouse; nonhuman; overall survival; proto oncogene; RNA sequencing; signal transduction; tumor growth; upregulation; uterine cervix cancer; Western blotting | English | 2022 | 2022-01-27 | 10.3389/fphar.2021.785981 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Article | Decisional balance, self-leadership, self-efficacy, planning, and stages of change in adopting exercise behaviors in patients with stomach cancer: A cross-sectional study | Purpose: Previous studies have suggested the benefits of regular exercise in motivating the survivors of cancer; however, most survivors are insufficiently active, showing high rates of nonadherence to physical activity guidelines. Using the I-Change model, this study sought to determine the association of decisional balance and self-efficacy for exercise, planning, and self-leadership with the stages of change in exercise behavior among patients with stomach cancer. Methods: This cross-sectional study was conducted in February 2021 and included 145 patients diagnosed with primary stomach cancer via quota sampling in South Korea. Sociodemographics, comorbidity, decisional balance for exercise, self-efficacy for exercise, planning, self-leadership, and stages of change in exercise behavior were assessed. Results: Of the participants, 4% were in the precontemplation stage of exercise behavior, 10% contemplation, 37% preparation, 23% action, and 27% maintenance. The male sex (p = 0.043), higher self-efficacy for resisting relapse (p < 0.0001), higher coping planning (p = 0.029), and higher self-leadership for behavior awareness and volition (p = 0.023) were associated with more readiness for changes in exercise behavior. Conclusions: From the results obtained using the I-Change model, self-efficacy for resisting relapse to previous habits, coping planning, and behavior awareness and volition were associated with more readiness for changes in exercise behavior. These findings may help reduce stomach cancer survivors' nonadherence to physical activity guidelines. | Lee, Myung Kyung | Kyungpook Natl Univ, Coll Nursing, Res Inst Nursing Sci, Daegu, South Korea | 40661513200 | mlee@knu.ac.kr; | EUROPEAN JOURNAL OF ONCOLOGY NURSING | EUR J ONCOL NURS | 1462-3889 | 1532-2122 | 56 | SCIE;SSCI | NURSING;ONCOLOGY | 2022 | 2.8 | 15.6 | 0.33 | 2025-06-25 | 4 | 2 | I-change model; Decisional balance; Physical activity; Planning; Self-efficacy; Self-leadership; Stages of change; Stomach cancer | QUALITY-OF-LIFE; PHYSICAL-ACTIVITY; PROSTATE-CANCER; INTERVENTION; DIFFERENCE; GUIDELINES; MANAGEMENT; SMOKING; MODEL; RISK | Decisional balance; I-change model; Physical activity; Planning; Self-efficacy; Self-leadership; Stages of change; Stomach cancer | Cross-Sectional Studies; Decision Making; Exercise; Health Behavior; Humans; Leadership; Male; Neoplasm Recurrence, Local; Self Efficacy; Stomach Neoplasms; Surveys and Questionnaires; Transtheoretical Model; cross-sectional study; decision making; exercise; health behavior; human; leadership; male; questionnaire; self concept; stomach tumor; tumor recurrence | English | 2022 | 2022-02 | 10.1016/j.ejon.2021.102086 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Review | Noncoding RNAs as a novel approach to target retinopathy of prematurity | Retinopathy of prematurity (ROP), a vascular disease characterized by abnormal vessel development in the retina, has become a primary cause of blindness in children around the world. ROP can be developed during two different phases: vessel loss and vessel proliferation. Once preterm infants with immature retinal vessel growth are exposed to high level of oxygen inside the incubator, vessel loss can occur. When infants are exposed to room air, they may experience the proliferation of vessels in the retina. Although multiple factors are reported to be involved in the pathogenesis of ROP, including vaso-endothelial growth factors (VEGFs) and hypoxia-inducible factors, the pathogenesis of ROP is not completely understood. Although laser therapy and pharmacologic agents, such as anti-VEGF agents, have been commonly used to treat ROP, the incidence of ROP is rapidly rising. Given that current therapies can be invasive and long-term effects are not fully known, the search for novel therapeutic targets with less destructive properties needs to be considered. Within the last decade, the field of noncoding RNA therapy has shown potential as next-generation therapy to treat diverse diseases. In this review, we introduce various noncoding RNAs regulating ROP and discuss their role as potential therapeutic targets in ROP. | Kim, Hyunjong; Kim, Jaesub; Ryu, Juhee | Kyungpook Natl Univ, Coll Pharm, Vessel Organ Interact Res Ctr, Daegu, South Korea; Kyungpook Natl Univ, Coll Pharm, Daegu, South Korea; Kyungpook Natl Univ, Res Inst Pharmaceut Sci, Daegu, South Korea | 57956633200; 57955718600; 57208255566 | juheeryu@knu.ac.kr; | FRONTIERS IN PHARMACOLOGY | FRONT PHARMACOL | 1663-9812 | 13 | SCIE | PHARMACOLOGY & PHARMACY | 2022 | 5.6 | 15.6 | 0.26 | 2025-06-25 | 5 | 5 | microRNA; long noncoding RNA; circular RNA; retinopathy of prematurity; retinal vascular disease; noncoding RNA | ENDOTHELIAL GROWTH-FACTOR; RETINAL NEOVASCULARIZATION; CIRCULAR RNAS; BEVACIZUMAB; THERAPEUTICS; MECHANISMS; MICRORNAS; CELLS; SERUM; HUMOR | circular RNA; long noncoding RNA; microRNA; noncoding RNA; retinal vascular disease; retinopathy of prematurity | aflibercept; angiopoietin 2; bevacizumab; brain derived neurotrophic factor; chemokine receptor CXCR4; circular ribonucleic acid; fibroblast growth factor 1; hypoxia inducible factor 1alpha; long untranslated RNA; metastasis associated lung adenocarcinoma transcript 1; microRNA; microRNA 145; microRNA 26a; Notch1 receptor; pegaptanib; ranibizumab; RNA induced silencing complex; unclassified drug; untranslated RNA; vasculotropin; vasculotropin A; vasculotropin inhibitor; blindness; human; hyperoxia; laser coagulation; nonhuman; oxygen-induced retinopathy; pathogenesis; Pi3K/Akt signaling; prematurity; retina blood vessel; retina neovascularization; retrolental fibroplasia; Review; sprouting angiogenesis; VEGF signaling | English | 2022 | 2022-10-20 | 10.3389/fphar.2022.1033341 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||||
| ○ | ○ | Article | Population Pharmacokinetic Model of AST-001, L-Isomer of Serine, Combining Endogenous Production and Exogenous Administration in Healthy Subjects | AST-001 is an L-isomer of serine that has protective effects on neurological disorders. This study aimed to establish a population pharmacokinetic (PK) model of AST-001 in healthy Korean to further propose a fixed-dose regimen in pediatrics. The model was constructed using 648 plasma concentrations from 24 healthy subjects, including baseline endogenous levels during 24 h and concentrations after a single dose of 10, 20, and 30 g of AST-001. For the simulation, an empirical allometric power model was applied to the apparent clearance and volume of distribution with body weight. The PK characteristics of AST-001 after oral administration were well described by a two-compartment model with zero-order absorption and linear elimination. The endogenous production of AST-001 was well explained by continuous zero-order production at a rate of 0.287 g/h. The simulation results suggested that 2 g, 4 g, 7 g, 10 g, and 14 g twice-daily regimens for the respective groups of 10-14 kg, 15-24 kg, 25-37 kg, 38-51 kg, 52-60 kg were adequate to achieve sufficient exposure to AST-001. The current population PK model well described both observed endogenous production and exogenous administration of AST-001 in healthy subjects. Using the allometric scaling approach, we suggested an optimal fixed-dose regimen with five weight ranges in pediatrics for the upcoming phase 2 trial. | Lee, Soyoung; Hwang, Su-Kyeong; Nam, Hee-Sook; Cho, Jung-Sook; Chung, Jae-Yong | Seoul Natl Univ, Coll Med, Dept Clin Pharmacol & Therapeut, Seoul, South Korea; Seoul Natl Univ, Med Res Ctr, Kidney Res Inst, Seoul, South Korea; Kyungpook Natl Univ, Dept Pediat, Sch Med, Daegu, South Korea; Astrogen Inc, Daegu, South Korea; Seoul Natl Univ, Bundang Hosp, Dept Clin Pharmacol & Therapeut, Seongnam, South Korea | Chung, Jae/J-5646-2012; Lee, Soyoung/ABC-4726-2021 | 57203597755; 37761570400; 57200286642; 57797675700; 7404003022 | jychung@snubh.org; | FRONTIERS IN PHARMACOLOGY | FRONT PHARMACOL | 1663-9812 | 13 | SCIE | PHARMACOLOGY & PHARMACY | 2022 | 5.6 | 15.6 | 0.4 | 2025-06-25 | 3 | 3 | population pharmacokinetics; L-serine; simulations; model-informed dose selection; autism | AUTISM SPECTRUM DISORDER; I CLINICAL-TRIAL; AMINO-ACIDS; L-ARGININE; BIOSYNTHESIS; METABOLISM; CHILDREN; GLYCINE; HUMANS; SAFETY | autism; L-serine; model-informed dose selection; population pharmacokinetics; simulations | ast 001; isoserine; neuroprotective agent; unclassified drug; adult; allometry; Article; autism; body weight; compartment model; controlled study; drug absorption; drug blood level; drug clearance; drug determination; drug dose regimen; drug elimination; human; human experiment; male; normal human; pharmacokinetic assay; population research; simulation; single drug dose; volume of distribution | English | 2022 | 2022-06-24 | 10.3389/fphar.2022.891227 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Article | Potential Adverse Events Reported With the Janus Kinase Inhibitors Approved for the Treatment of Rheumatoid Arthritis Using Spontaneous Reports and Online Patient Reviews | The aim of this study was to analyze the potential adverse events (AEs) caused by Janus kinase (JAK) inhibitors, including tofacitinib, baricitinib, and upadacitinib, used to treat rheumatoid arthritis using spontaneous AE reports from the FDA (FAERS) and interpreting them in correlation with those from Korea (KAERS) and an online patient review (WebMD). Potential AEs were identified based on a disproportionality analysis using the proportional reporting ratio (PRR), reporting odds ratio (ROR), and the information component (IC). A total of 23,720 reports were analyzed from FAERS database, of which 91.5% were reports on tofacitinib. Potentially important medical AEs related to infections were reported frequently, as well as thromboembolism-related AEs. The AEs, such as malignancy, interstitial lung diseases, myocardial infarction, and gastrointestinal disorder, also reported. In an online patient review report, the ineffectiveness of the drug and gastrointestinal AEs were frequently reported. Infection with baricitinib and symptoms related to pain or edema due to upadacitinib were the main discomfort experienced by patients. In conclusion, the results of this study highlight the possible safety issues associated with JAK inhibitors. Routine clinical observations and further research using various real-world databases are needed. | Song, Yun-Kyoung; Song, Junu; Kim, Kyungim; Kwon, Jin-Won | Daegu Catholic Univ, Coll Pharm, Gyongsan, South Korea; Univ Southern Calif, Viterbi Sch Engn, Dept Comp Sci, Los Angeles, CA 90007 USA; Korea Univ, Coll Pharm, Sejong, South Korea; Korea Univ, Inst Pharmaceut Sci, Sejong, South Korea; Kyungpook Natl Univ, Coll Pharm, BK21 FOUR Community Based Intelligent Novel Drug, Daegu, South Korea; Kyungpook Natl Univ, Res Inst Pharmaceut Sci, Daegu, South Korea | Kim, Honghyok/LDF-5356-2024 | 56136407200; 57426068900; 36164229800; 16202951700 | jwkwon@knu.ac.kr; | FRONTIERS IN PHARMACOLOGY | FRONT PHARMACOL | 1663-9812 | 12 | SCIE | PHARMACOLOGY & PHARMACY | 2022 | 5.6 | 15.6 | 3.07 | 2025-06-25 | 21 | 24 | Janus kinase inhibitors; rheumatoid arthritis; adverse event reporting systems; online patient reviews; potential adverse events | DRUG-REACTIONS; JAK INHIBITORS | adverse event reporting systems; Janus kinase inhibitors; online patient reviews; potential adverse events; rheumatoid arthritis | baricitinib; tofacitinib; upadacitinib; adult; adverse event; Article; breast cancer; cataract; cellulitis; deep vein thrombosis; diabetes mellitus; diverticulitis; drug safety; female; health service; heart infarction; hematochezia; human; incidence; interstitial lung disease; kidney failure; kidney infection; Korea; lung embolism; major clinical study; male; middle aged; nephrolithiasis; online monitoring; pneumonia; respiratory failure; retrospective study; rheumatoid arthritis; sepsis; systemic lupus erythematosus; thrombosis; unconsciousness; United States; web-based intervention | English | 2022 | 2022-01-11 | 10.3389/fphar.2021.792877 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Article | Real-world association of adherence with outcomes and economic burden in patients with tuberculosis from South Korea claims data | Objectives: We analyzed tuberculosis (TB)-related costs according to treatment adherence, as well as the association between treatment adherence, treatment outcomes, and costs related to drug-susceptible TB in South Korea. Methods: Patients who had newly treated TB in South Korea between 2006 and 2015 were selected from nationwide sample claims data and categorized into adherent and non-adherent groups using the proportion of days TB drugs covered. Patients were followed-up from the initiation of TB treatment. The mean five-year cumulative costs per patient were estimated according to adherence. Moreover, we evaluated the relative ratios to identify cost drivers such as adherence, treatment outcomes, and baseline characteristics using generalized linear models. Four treatment outcomes were included: treatment completion, loss to follow-up, death, and the initiation of multidrug-resistant TB treatment. Results: Out of the 3,799 new patients with TB, 2,662 were adherent, and 1,137 were non-adherent. Five years after initiating TB treatment, the mean TB-related costs were USD 2,270 and USD 2,694 in the adherent and non-adherent groups, respectively. The TB-related monthly cost per patient was also lower in the adherent than in the non-adherent (relative ratio = 0.89, 95% CI 0.92-0.98), while patients who were lost to follow-up spent more on TB-related costs (2.52, 2.24-2.83) compared to those who completed the treatment. Conclusion: Non-adherent patients with TB spend more on treatment costs while they have poorer outcomes compared to adherent patients with TB. Improving patient adherence may lead to effective treatment outcomes and reduce the economic burden of TB. Policymakers and providers should consider commitment programs to improve patient's adherence. | Kwon, Sun-Hong; Nam, Jin Hyun; Kim, Hye-Lin; Park, Hae-Young; Kwon, Jin-Won | Sungkyunkwan Univ, Sch Pharm, Suwon, South Korea; Korea Univ, Div Big Data Sci, Sejong Campus, Sejong, South Korea; Sahmyook Univ, Coll Pharm, Seoul, South Korea; Kyungpook Natl Univ, Coll Pharm, BK21 FOUR Community Based Intelligent Novel Drug D, Daegu, South Korea; Kyungpook Natl Univ, Res Inst Pharmaceut Sci, Daegu, South Korea | Kwon, Sun-Hong/KFS-7860-2024; Kim, Chang/G-5001-2015 | 56010779700; 57193239694; 57203629752; 57203771734; 16202951700 | jwkwon@knu.ac.kr; | FRONTIERS IN PHARMACOLOGY | FRONT PHARMACOL | 1663-9812 | 13 | SCIE | PHARMACOLOGY & PHARMACY | 2022 | 5.6 | 15.6 | 0.53 | 2025-06-25 | 4 | 4 | adherence; tuberculosis; cost; treatment outcome; re-treatment | PUBLIC-PRIVATE MIX; WESTERN CAPE; IMPACT; COSTS; CARE | adherence; cost; re-treatment; treatment outcome; tuberculosis | ethambutol; isoniazid; pyrazinamide; rifabutin; rifampicin; adult; aged; Article; clinical feature; cohort analysis; controlled study; drug sensitivity; female; follow up; health care cost; health economics; health insurance; human; major clinical study; male; mortality; multidrug resistant tuberculosis; outcome assessment; patient compliance; retrospective study; sex difference; South Korea; treatment outcome; tuberculosis; very elderly | English | 2022 | 2022-08-16 | 10.3389/fphar.2022.918344 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Article | Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score-matched retrospective cohort study | Background: Regdanvimab (CT-P59) is a neutralizing antibody authorized in Republic of Korea for the treatment of adult patients with moderate or mild-COVID-19 who are not on supplemental oxygen and have high risk of progressing to severe disease (age & GE; 50 years or comorbidities). This study evaluated the clinical efficacy, safety and medical utilization/costs associated with real-world regdanvimab therapy.& nbsp;Methods: This non-interventional, retrospective cohort study included adult patients with confirmed mild-to moderate SARS-CoV-2 infection. Patients treated with regdanvimab were compared with controls who had received other therapies. The primary endpoint was the proportion of patients progressing to severe/critical COVID-19 or death due to SARS-CoV-2 infection up to Day 28. Propensity score matching was applied to efficacy analyses.& nbsp;Results: Overall, 552 patients were included in the Safety and Efficacy Sets (regdanvimab, n = 156; control, n = 396) and 274 patients in the propensity score-matched (PSM) Efficacy Set (regdanvimab, n = 113; control, n = 161). In the PSM Set, the risk of severe/critical COVID-19 or death was significantly lower in the regdanvimab group (7.1% vs 16.1%, P = 0.0263); supplemental oxygen was required by 8.0% and 18.6% of patients in the regdanvimab and control groups, respectively (P = 0.0128). There were no unexpected safety findings in the regdanvimab group. Medical utilization analysis showed an overall cost reduction with regdanvimab compared with control treatments.& nbsp;Conclusions: Regdanvimab significantly reduced the proportion of patients progressing to severe/critical disease or dying of SARS-CoV-2 infection. This study shows the potential benefits of regdanvimab in reducing disease severity and improving medical utility in patients with COVID-19. | Lee, Shinwon; Lee, Soon Ok; Lee, Jeong Eun; Kim, Kye-Hyung; Lee, Sun Hee; Hwang, Soyoon; Kim, Shin-Woo; Chang, Hyun-Ha; Kim, Yoonjung; Bae, Sohyun; Kim, A-Sol; Kwon, Ki Tae | Pusan Natl Univ, Sch Med, Dept Internal Med, Busan, South Korea; Pusan Natl Univ Hosp, Med Res Inst, Busan, South Korea; Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Div Infect Dis,Dept Internal Med, Daegu, South Korea; Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Div Infect Dis,Dept Internal Med, Daegu, South Korea; Kyungpook Natl Univ, Sch Med, Chilgok Hosp, Dept Family Med, Daegu, South Korea | ; Hwang, Soyoon/HHM-5762-2022; LEE, SUN HEE/AAB-5714-2022; Kim, So/AAS-1630-2021; Kim, Ji Hoon/AAB-4602-2022 | 24479446100; 57208338348; 56007173000; 7409324883; 56498686800; 57203160675; 8710731500; 7407521688; 57203160508; 57219699506; 57203290656; 9733850500 | ktkwon@knu.ac.kr; | INTERNATIONAL IMMUNOPHARMACOLOGY | INT IMMUNOPHARMACOL | 1567-5769 | 1878-1705 | 106 | SCIE | IMMUNOLOGY;PHARMACOLOGY & PHARMACY | 2022 | 5.6 | 15.6 | 1.03 | 2025-06-25 | 10 | 11 | COVID-19; CT-P59; Pneumonia; Outcome | COVID-19 | COVID-19; CT-P59; Outcome; Pneumonia | Adult; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; COVID-19; Humans; Immunoglobulin G; Middle Aged; Propensity Score; Retrospective Studies; SARS-CoV-2; angiotensin converting enzyme 2; corticosteroid; ct p 59; immunoglobulin Fc fragment; oxygen; regdanvimab; remdesivir; SARS-CoV-2 vaccine; immunoglobulin G; monoclonal antibody; neutralizing antibody; regdanvimab; adult; aged; Article; clinical evaluation; cohort analysis; comparative study; controlled study; coronavirus disease 2019; drug efficacy; drug safety; female; health care cost; health care utilization; human; hypertension; hypoxia; major clinical study; male; pneumonia; propensity score; retrospective study; risk assessment; risk factor; Severe acute respiratory syndrome coronavirus 2; drug therapy; middle aged | English | 2022 | 2022-05 | 10.1016/j.intimp.2022.108570 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Sargahydroquinoic acid isolated from Sargassum serratifolium as inhibitor of cellular basophils activation and passive cutaneous anaphylaxis in mice | Basophils and mast cells are characteristic effector cells in allergic reactions. Sargahydorquinoic acid (SHQA), a compound isolated from Sargassum serratifolium (marine alga), possesses various biochemical properties, including potent antioxidant activities. The objective of the present study was to investigate inhibitory effects of SHQA on the activation of human basophilic KU812F cells induced by phorbol myristate acetate and A23187 (PMACI), a calcium ionophore. Furthermore, we confirmed the inhibitory effects of SHQA on the activation of rat basophilic leukemia (RBL)-2H3 cells induced by compound 48/80 (com 48/80), bone marrow-derived mast cells (BMCMCs) induced by anti-dinitrophenyl(DNP)-immunoglobulin E (IgE)/DNP-bovine serum albumin (BSA), DNP/IgE and on the reaction of passive cutaneous anaphylaxis (PCA) mediated by IgE. SHQA reduced PMACIinduced intracellular reactive oxygen species (ROS) and calcium levels. Western blot analysis revealed that SHQA downregulated the activation of ERK, p38, and NF-cB in a dose-dependent manner. Moreover, SHQA suppressed the production and gene expression of various cytokines, including interleukin (IL)-1 13, IL-4, IL-6, and IL-8 in PMACI-induced KU812F cells and IL-4 and tumor necrosis factor (TNF)-alpha in com 48/80-induced RBL-2H3 cells. It also determined the inhibition of PMACI, com 48/80-and IgE/DNP-induced degranulation by reducing the release of 13-hexosaminidase. Furthermore, it attenuated the IgE/DNP-induced PCA reaction in the ears of BALB/c mice. These results suggest that SHQA isolated from S. serratifolium is a potential therapeutic functional food material for inhibiting effector cell activation in allergic reactions and anaphylaxis in animal model. | Choi, Kap Seong; Shin, Tai-Sun; Chun, Jiyeon; Ahn, Ginnae; Han, Eui Jeong; Kim, Min-Jong; Kim, Jung-Beom; Kim, Sang-Hyun; Kho, Kang-Hee; Kim, Dae Heon; Shim, Sun-Yup | Sunchon Natl Univ, Dept Food Sci & Biotechnol, Sunchon 57922, South Korea; Chonnam Natl Univ, Div Food & Nutr, Gwangju 61186, South Korea; Chonnam Natl Univ, Dept Marine Biofood Sci, Yeosu 59626, South Korea; Chonnam Natl Univ, Res Ctr Healthcare & Biomed Engn, Yeosu 59626, South Korea; Chonnam Natl Univ, Dept Food Technol & Nutr, Yeosu 59626, South Korea; Kyungpook Natl Univ, Cell & Matrix Res Inst, Dept Pharmacol, Sch Med, Daegu, South Korea; Chonnam Natl Univ, Coll Fisheries & Ocean Sci, Dept Fisheries Sci, Yeosu 59626, South Korea; Sunchon Natl Univ, Dept Biol, Sunchon 57922, South Korea | Kho, Kang Hee/AAA-2634-2022; Kim, Tae/C-5935-2015 | 7403949328; 7201493134; 8729213500; 21933616400; 57431075200; 57192888932; 57431669300; 57210450420; 56187281000; 56984358300; 7202796140 | shimsy@scnu.ac.kr; | INTERNATIONAL IMMUNOPHARMACOLOGY | INT IMMUNOPHARMACOL | 1567-5769 | 1878-1705 | 105 | SCIE | IMMUNOLOGY;PHARMACOLOGY & PHARMACY | 2022 | 5.6 | 15.6 | 1.4 | 2025-06-25 | 13 | 15 | Sargahydroquinoic acid; Sargassum serratifolium; Basophils; Degranulation; Cytokines; Passive cutaneous anaphylaxis | KAPPA-B-ALPHA; FC-EPSILON-RI; MAST-CELLS; SARGAQUINOIC ACID; ETHANOLIC EXTRACT; OXIDATIVE STRESS; PERITONEAL-MACROPHAGES; REACTIVE OXYGEN; CONTRIBUTE; CYTOKINES | Basophils; Cytokines; Degranulation; Passive cutaneous anaphylaxis; Sargahydroquinoic acid; Sargassum serratifolium | Alkenes; Anaphylaxis; Animals; Basophils; Benzoquinones; Mast Cells; Mice; Mice, Inbred BALB C; Passive Cutaneous Anaphylaxis; Rats; Sargassum; beta n acetylhexosaminidase; bovine serum albumin; calcium; chemical compound; compound 48-80; cytokine; dinitrophenyl antibody; endogenous compound; immunoglobulin E; immunoglobulin enhancer binding protein; interleukin 1beta; interleukin 4; interleukin 6; interleukin 8; mitogen activated protein kinase 1; phorbol 13 acetate 12 myristate; reactive oxygen metabolite; sargahydroquinoic acid; tumor necrosis factor; unclassified drug; alkene; benzoquinone derivative; sargahydroquinoic acid; allergic reaction; animal cell; animal experiment; animal model; antioxidant activity; Article; Bagg albino mouse; basophil degranulation; bone marrow derived mast cell; calcium transport; cell activation; controlled study; degranulation assay; effector cell; enzyme linked immunosorbent assay; functional food; gene expression; male; mast cell leukemia; mouse; nonhuman; passive skin anaphylaxis; protein expression; RBL-2H3 cell line; reverse transcription polymerase chain reaction; Sargassum; Western blotting; anaphylaxis; animal; basophil; mast cell; metabolism; passive skin anaphylaxis; rat | English | 2022 | 2022-04 | 10.1016/j.intimp.2022.108567 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Guideline for the treatment of no light perception eyes induced by mechanical ocular trauma | Severe mechanical ocular trauma with no light perception (NLP) predicts a poor prognosis of visual acuity and enucleation of the eyeball. Since the innovative treatment concept of exploratory vitreoretinal surgery has developed and treatment technology has advanced, the outcomes of severe ocular trauma treatment in NLP patients have greatly improved. However, there remains a lack of unified standards for the determination, surgical indication, and timing of vitrectomy in NLP eye treatment. To address these problems, we aimed to create evidence-based medical guidelines for the diagnosis, treatment, and prognosis of mechanical ocular trauma with NLP. Sixteen relevant recommendations for mechanical ocular trauma with NLP were obtained, and a consensus was reached. Each recommendation was explained in detail to guide the treatment of mechanical ocular trauma associated with NLP. | Yan, Hua; Yang, Kehu; Ma, Zhizhong; Kuhn, Ferenc; Zhang, Wenfang; Wang, ZhiJun; Hu, Yuntao; Lu, Hai; Shigeo, Yoshida; Sobaci, Gungor; Ozdek, Sengul; Forlini, Matteo; Huang, Bo; Hui, Yannian; Zhang, Ming; Xu, Gezhi; Wei, Wenbin; Jiang, Yanrong; Park, DongHo; Fernandes, RodrigoAntonio Brant; He, Yuguang; Rousselot, Andres; Hoskin, Annette; Sundar, Gangadhara; Liu, Yong; Wang, Yusheng; Shen, Lijun; Chen, Haoyu; Chen, Huijin; Han, Gezhi; Jiang, Rui; Jin, Xuemin; Lin, Jijian; Luo, Jing; Wang, Zhaoyang; Wei, Yong; Wen, Ying; Xie, Zhenggao; Wang, Yi; Yang, Xun; Yu, Wenzhen; Zheng, Zhi; Sun, Xiaodong; Liang, Jianhong; Liu, Qin; Yu, Jinguo; Wei, Shihui; Li, Zhengxiang; Chen, Lu; Wang, Xiufen; Wei, Lili; Zhang, Haokun; Chen, Siyue; Liu, Yuming; Guo, Xu; Liu, Siyuan; Xu, Xinhua; Tao, Yibo; Chen, Yixuan; Chen, Yaolong | Tianjin Med Univ Gen Hosp, Dept Ophthalmol, Tianjin 300052, Peoples R China; Nankai Univ, Sch Med, Tianjin, Peoples R China; Lanzhou Univ, Evidence Based Med Ctr, Sch Basic Med Sci, Lanzhou, Peoples R China; Lanzhou Univ, WHO Collaborating Ctr Guideline Implementat & Kno, Lanzhou, Peoples R China; Peking Univ Third Hosp, Peking Univ Eye Ctr, Beijing, Peoples R China; Helen Keller Fdn Res & Educ, Dept Ophthalmol Res, Birmingham, AL USA; Lanzhou Univ Second Hosp, Dept Ophthalmol, Lanzhou, Peoples R China; China Japan Friendship Hosp, Dept Ophthalmol, Beijing, Peoples R China; Tsinghua Univ, Beijing Tisnghua Changgung Hosp, Sch Clin Med, Dept Ophthalmol, Beijing, Peoples R China; Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Ophthalmol & Visual Sci Key Lab, Beijing, Peoples R China; Kurume Univ, Sch Med, Dept Ophthalmol, Kurume, Fukuoka, Japan; Hacettepe Univ, Fac Med, Dept Ophthalmol, Ankara, Turkey; Gazi Univ, Fac Med, Dept Ophthalmol, Ankara, Turkey; Domus Nova Hosp, Dept Ophthalmol, Ravenna, Italy; Osped Stato Repubbl San Marino, Dept Ophthalmol, Ravenna, Italy; Univ Mississippi, Med Ctr, Dept Ophthalmol, Jackson, MS 39216 USA; Fourth Mil Med Univ, Xijing Hosp, Eye Inst Chinese PLA, Dept Ophthalmol, Xian, Peoples R China; Sichuan Univ, Dept Ophthalmol, West China Hosp, Chengdu, Peoples R China; Fudan Univ, Eye & ENT Hosp, Eye Inst, Shanghai, Peoples R China; Fudan Univ, Eye & ENT Hosp, Dept Ophthalmol, Shanghai, Peoples R China; Peking Univ Peoples Hosp, Eye Dis & Optometry Inst, Dept Ophthalmol, Beijing, Peoples R China; Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Ophthalmol, Daegu, South Korea; Univ Fed Sao Paulo, Dept Ophthalmol & Visual Sci, Escola Paulista Med, Sao Paulo, SP, Brazil; UT Southwestern Med Ctr, Dept Ophthalmol, Dallas, TX USA; Univ Salvador, Dept Ophthalmol, Buenos Aires, DF, Argentina; Univ Sydney, Save Sight Inst, Sydney, NSW, Australia; Natl Univ Singapore Hosp, Dept Ophthalmol, Singapore, Singapore; Army Med Univ PLA, Affiliated Hosp 1, Dept Ophthalmol, Chongqing, Peoples R China; Wenzhou Med Univ, Sch Ophthalmol, Wenzhou, Peoples R China; Wenzhou Med Univ, Eye Hosp, Wenzhou, Peoples R China; Shantou Univ & Chinese Univ Hong Kong, Joint Shantou Int Eye Ctr, Shantou, Peoples R China; Tianjin Med Univ, Tianjin Key Lab Ophthalmol & Visual Sci, Clin Coll Ophthalmol, Tianjin Eye Inst,Tianjin Eye Hosp, Tianjin, Peoples R China; Zhengzhou Univ, Affiliated Hosp 1, Dept Ophthalmol, Henan Prov Eye Hosp,Henan Int Joint Res Lab Ocula, Zhengzhou, Peoples R China; Zhejiang Univ, Affiliated Hosp 2, Eye Ctr, Sch Med, Hangzhou, Peoples R China; Cent South Univ, Xiangya Hosp 2, Dept Ophthalmol, Changsha, Peoples R China; Tongji Univ, Dept Ophthalmol, Shanghai Peoples Hosp 10, Shanghai, Peoples R China; Shandong Univ Tradit Chinese Med, Affiliated Eye Hosp, Dept Ophthalmol, Jinan, Peoples R China; Nanjing Univ, Affiliated Hosp, Med Sch, Dept Ophthalmol,Nanjing Drum Tower Hosp, Nanjing, Peoples R China; Cent South Univ, Chongqing Aier Gen Hosp, Aier Sch Ophthalmol, Chongqing, Peoples R China; Soochow Univ, LiXiang Eye Hosp, Dept Fundus Dis & Ocular Trauma, Suzhou, Peoples R China; Shanghai Gen Hosp, Dept Ophthalmol, Shanghai, Peoples R China; Gansu Prov Hosp, Dept Ophthalmol, Lanzhou, Peoples R China; Chinese Peoples Liberat Army Gen Hosp, Dept Neuroophthalmol, Beijing, Peoples R China; Nankai Univ, Sch Finance, Tianjin, Peoples R China | ; Wei, Shihui/NBY-2986-2025; Özdek, Şengül/CAI-1797-2022; Rousselot, Andres/AAS-8604-2021; Forlini, Matteo/AAA-2402-2020; Zhang, Haokun/GLN-7046-2022; Brant, Rodrigo/AAR-1878-2021; Hoskin, Annette/S-9200-2019; Chen, Haoyu/A-7432-2013; Wang, zhijun/G-8543-2015; Lu, Hai/MFI-3034-2025; Chung, Yih/AIF-2414-2022; Huang, Bo/LIC-1378-2024 | 35276682300; 58453790400; 7403600398; 55798501200; 23101877700; 56645988900; 56688751900; 7404843429; 57908593100; 6602152179; 6701422317; 24504322000; 57215488292; 54390980100; 56796912200; 7404264279; 14068232700; 55545073200; 36676632900; 57217797529; 7404942811; 57203862663; 56287893800; 21735507700; 56008336900; 25825764800; 14527863800; 15062457500; 56068438700; 57908593200; 57202916205; 8877879400; 7501719549; 57304774900; 34876018800; 55623357700; 55237376200; 16317848400; 59662426300; 57211845053; 8243770100; 55329682400; 57205479954; 8874889100; 56127863300; 23053345200; 7401765485; 57191968175; 59627195100; 57909635200; 57201272572; 57237777000; 57909005500; 57909425200; 57909005600; 57909635300; 57908801800; 57910064900; 57909635400; 55174851300 | zyyyanhua@tmu.edu.cn;yangkehu-ebm@lzu.edu.cn; | JOURNAL OF EVIDENCE BASED MEDICINE | J EVID-BASED MED | 1756-5383 | 1756-5391 | 15 | 3 | SCIE | MEDICINE, GENERAL & INTERNAL | 2022 | 7.3 | 15.7 | 1.46 | 2025-06-25 | 11 | 12 | evidence-based medicine; mechanical ocular trauma; no light perception; treatment guidelines | OPEN-GLOBE INJURY; SILICONE OIL TAMPONADE; INTRAOCULAR FOREIGN-BODIES; PARS-PLANA VITRECTOMY; FINAL VISUAL-ACUITY; PROGNOSTIC-FACTORS; POSTTRAUMATIC ENDOPHTHALMITIS; SURGICAL-TREATMENT; RISK-FACTORS; MANAGEMENT | evidence-based medicine; mechanical ocular trauma; no light perception; treatment guidelines | Eye Injuries, Penetrating; Humans; Prognosis; Retrospective Studies; Visual Acuity; Vitrectomy; antibiotic agent; corticosteroid; silicone oil; afferent pupillary defect; anamnesis; anesthesia; Article; cataract; choroid detachment; choroid prolapse; cornea edema; endophthalmitis; eye enucleation; eye examination; eye injury; follow up; human; hyphema; iatrogenic retinal tear; informed consent; intraocular foreign body; intraocular hemorrhage; intraocular pressure abnormality; lens disease; mechanical ocular trauma; medical history; no light perception; operative blood loss; peroperative complication; practice guideline; preoperative evaluation; prognosis; prophylaxis; retina detachment; retina hemorrhage; retina prolapse; risk factor; rupture; salvage therapy; surgical technique; treatment indication; visual acuity; visual impairment; vitrectomy; vitreoretinopathy; vitreous hemorrhage; vitreous prolapse; wound length; zone III injury; eye injury; retrospective study | English | 2022 | 2022-09 | 10.1111/jebm.12496 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | Article | Mixed-Reference Spin-Flip Time-Dependent Density Functional Theory for Accurate X-ray Absorption Spectroscopy | It is demonstrated that the challenging core-hole particle (CHP) orbital relaxation for core electron spectra can be readily achieved by the mixed-reference spin-flip (MRSF)-time-dependent density functional theory (TDDFT). With the additional scalar relativistic effects on K-edge excitation energies of 24 second- and 17 third-row molecules, the particular ΔCHP-MRSF(R) exhibited near perfect predictions with RMSE ∼0.5 eV, featuring a median value of 0.3 and an interquartile range of 0.4. Overall, the CHP effect is 2-4 times stronger than relativistic ones, contributing more than 20 eV in the cases of sulfur and chlorine third-row atoms. Such high precision allows to explain the splitting and spectral shapes of O, N, and C atom K-edges in the ground state of thymine with atom as well as orbital specific accuracy. The same protocol with a double hole particle relaxation also produced remarkably accurate K-edge spectra of core to valence hole excitation energies from the first (nO8π∗) and second (ππ∗) excited states of thymine, confirming the assignment of 1s → n excitation for the experimentally observed 526.4 eV peak. Regarding both accuracy and practicality, therefore, MRSF-TDDFT provides a promising protocol for core electron spectra of both ground and excited electronic states alike. © 2022 American Chemical Society. All rights reserved. | Park, Woojin; Alías-Rodríguez, Marc; Cho, Daeheum; Lee, Seunghoon; Huix-Rotllant, Miquel; Choi, Cheol Ho | Department of Chemistry, Kyungpook National University, Daegu, 41566, South Korea; Aix-Marseille Univ, CNRS, Institut de Chimie Radicalaire, Marseille, 13284, France; Department of Chemistry, Kyungpook National University, Daegu, 41566, South Korea; Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, 91125, CA, United States; Aix-Marseille Univ, CNRS, Institut de Chimie Radicalaire, Marseille, 13284, France; Department of Chemistry, Kyungpook National University, Daegu, 41566, South Korea | 57223952329; 57204724834; 55263218400; 57194591254; 25634188900; 7402958948 | cchoi@knu.ac.kr;miquel.huix-rotllant@cnrs.fr; | Journal of Chemical Theory and Computation | J CHEM THEORY COMPUT | 1549-9618 | 1549-9626 | 18 | 10 | SCIE | CHEMISTRY, PHYSICAL;PHYSICS, ATOMIC, MOLECULAR & CHEMICAL | 2022 | 5.5 | 15.7 | 1.42 | 2025-06-25 | 16 | Chlorine; Density Functional Theory; Sulfur; Thymine; X-Ray Absorption Spectroscopy; chlorine; sulfur; thymine; density functional theory; X ray absorption spectroscopy | English | Final | 2022 | 10.1021/acs.jctc.2c00746 | 바로가기 | 바로가기 | 바로가기 | ||||||||
| ○ | ○ | Review | Recent Progress of Triboelectric Nanogenerators for Biomedical Sensors: From Design to Application | Triboelectric nanogenerators (TENG) have gained prominence in recent years, and their structural design is crucial for improvement of energy harvesting performance and sensing. Wearable biosensors can receive information about human health without the need for external charging, with energy instead provided by collection and storage modules that can be integrated into the biosensors. However, the failure to design suitable components for sensing remains a significant challenge associated with biomedical sensors. Therefore, design of TENG structures based on the human body is a considerable challenge, as biomedical sensors, such as implantable and wearable self-powered sensors, have recently advanced. Following a brief introduction of the fundamentals of triboelectric nanogenerators, we describe implantable and wearable self-powered sensors powered by triboelectric nanogenerators. Moreover, we examine the constraints limiting the practical uses of self-powered devices. | Sardo, Fatemeh Rahimi; Rayegani, Arash; Nazar, Ali Matin; Balaghiinaloo, Mohammadali; Saberian, Mohammadhossein; Mohsan, Syed Agha Hassnain; Alsharif, Mohammed H.; Cho, Ho-Shin | Shahid Bahonar Univ Kerman, Dept Min Engn, Kerman 7616913439, Iran; Sharif Univ Technol, Dept Civil Engn, Azadi Ave, Tehran 1458889694, Iran; Zhejiang Univ, Ocean Coll, Zhoushan 316021, Peoples R China; Fasa Univ Med Sci, Sch Med, Fasa 7461686688, Iran; Zhejiang Univ, Sch Med, 866 Yuhangtang Rd, Hangzhou 310058, Peoples R China; Sejong Univ, Coll Elect & Informat Engn, Dept Elect Engn, Seoul 05006, South Korea; Kyungpook Natl Univ, Sch Elect & Elect Engn, Daegu 41566, South Korea | MATIN NAZAR, ALI/MTA-7287-2025; Alsharif, Mohammed H./X-7516-2018; Mohsan, Syed Agha Hassnain/AAF-4602-2021; Rayegani, Arash/HHS-9994-2022 | 57897148100; 57219114750; 56108250000; 57218464966; 57896669800; 57218375194; 55968967000; 35316924900 | hscho@ee.knu.ac.kr; | BIOSENSORS-BASEL | BIOSENSORS-BASEL | 2079-6374 | 12 | 9 | SCIE | CHEMISTRY, ANALYTICAL;INSTRUMENTS & INSTRUMENTATION;NANOSCIENCE & NANOTECHNOLOGY | 2022 | 5.4 | 15.7 | 1.32 | 2025-06-25 | 33 | 36 | triboelectric nanogenerators (TENG); self-powered sensors; biomedical sensors | SHOE INSOLE; ENERGY; OUTPUT; EFFICIENT; PERFORMANCE; WIRELESS; SYSTEM; SIMULATION; DEVICES; DISEASE | biomedical sensors; self-powered sensors; triboelectric nanogenerators (TENG) | Biosensing Techniques; Electric Power Supplies; Humans; Nanotechnology; Prostheses and Implants; Biosensors; Structural design; Triboelectricity; Wearable sensors; Biomedical sensors; Energy; Human health; Nanogenerators; Performance; Recent progress; Self-powered; Self-powered sensor; Storage modules; Triboelectric nanogenerator; breathing; equipment design; health care; heart rate; human; monitoring; muscle excitation; nerve stimulation; Review; genetic procedures; nanotechnology; power supply; prostheses and orthoses; Nanogenerators | English | 2022 | 2022-09 | 10.3390/bios12090697 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | Review | Self-forming Dynamic Membranes for Wastewater Treatment | Introduction: Self-forming dynamic membrane (SFDM) technology has been gaining significant interest due to its potential advantages, notably lower capital and operational cost and easier fouling control, over conventional membranes used in membrane bioreactors. SFDM technology utilizes inexpensive support material integrated with a dynamic membrane (DM) made of suspended solids and biomass to provide high effluent quality. Objectives: This paper aims to bridge the gap between the previous reviews and the current studies to provide a comprehensive review on SFDM applications to both aerobic and anaerobic bioreactors. Literature review: The historical development of DMs since the 1960s up to the present is presented. Specific attention was given to DM formation mechanisms, deposition time, impacts of design, and operational factors (mesh characteristics and sludge properties) on DM formation and performances and on DM-based integrated systems. Abbreviations: AnDMBR, anaerobic dynamic membrane bioreactor; CFV,crossflow velocity; COD,chemical oxygen demand; DM,dynamic membrane; DO,dissolved oxygen; EPS,extracellular polymeric substances; F/M,food to microorganisms ratio; HRT,hydraulic retention time; J,flux; MBR,membrane bioreactor; MF,microfiltration; MLSS,mixed liquor suspended solids; PSD,particle size distribution; RO,reverse osmosis; SEM,scanning electron microscopy; SFDM,self-forming dynamic membrane; SMP,soluble microbial products; SRT,sludge retention time; SS,suspended solids; TMP,transmembrane pressure; TN,total nitrogen; TP,total phosphorus; TSS,total suspended solids; UF,ultrafiltration. © 2021 Taylor & Francis Group, LLC. | Millanar-Marfa, Jessa Marie J.; Borea, Laura; Castrogiovanni, Fabiano; Hasan, Shadi Wajih; Choo, Kwang-Ho; Korshin, Gregory V.; de Luna, Mark Daniel G.; Ballesteros, Florencio C.; Belgiorno, Vincenzo; Naddeo, Vincenzo | Environmental Engineering Program, National Graduate School of Engineering, University of the Philippines, Quezon City, Philippines; Sanitary Environmental Engineering Division (SEED), Department of Civil Engineering, University of Salerno, Fisciano, Italy; Sanitary Environmental Engineering Division (SEED), Department of Civil Engineering, University of Salerno, Fisciano, Italy; Center for Membrane and Advanced Water Technology (CMAT), Department of Chemical Engineering, Khalifa University of Science and Technology, Masdar City Campus, Abu Dhabi, United Arab Emirates; Department of Environmental Engineering, Kyungpook National University (KNU), Bukgu Daegu, South Korea; Department of Civil and Environmental Engineering, University of Washington, Seattle, WA, United States; Environmental Engineering Program, National Graduate School of Engineering, University of the Philippines, Quezon City, Philippines; Jr., Environmental Engineering Program, National Graduate School of Engineering, University of the Philippines, Quezon City, Philippines; Sanitary Environmental Engineering Division (SEED), Department of Civil Engineering, University of Salerno, Fisciano, Italy; Sanitary Environmental Engineering Division (SEED), Department of Civil Engineering, University of Salerno, Fisciano, Italy | 57207260926; 56442610000; 57221015267; 35738779100; 7102083272; 7003696629; 36954504500; 36664314600; 6508019638; 57225215311 | vnaddeo@unisa.it; | Separation and Purification Reviews | SEP PURIF REV | 1542-2119 | 1542-2127 | 51 | 2 | SCIE | CHEMISTRY, ANALYTICAL;CHEMISTRY, APPLIED;ENGINEERING, CHEMICAL | 2022 | 5.4 | 15.7 | 0.54 | 2025-06-25 | 18 | bioreactors; Dynamic membrane; extracellular polymeric substances; flux; membrane fouling; sludge properties | Activated sludge process; Bioconversion; Bioreactors; Chemical oxygen demand; Dissolved oxygen; Effluents; Microfiltration; Particle size; Particle size analysis; Scanning electron microscopy; Wastewater treatment; Water quality; Aerobic and anaerobic bioreactors; Dynamic membrane bioreactors; Extra-cellular polymeric substances; Hydraulic retention time; Mixed liquor suspended solids; Self-forming dynamic membranes (SFDM); Soluble microbial products; Transmembrane pressures; Membranes | English | Final | 2022 | 10.1080/15422119.2021.1887223 | 바로가기 | 바로가기 | 바로가기 |
페이지 이동: